Literature DB >> 13130484

Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes.

Ebun Aganna1, Linda Hammond, Philip N Hawkins, Anna Aldea, Shane A McKee, Hans Kristian Ploos van Amstel, Claudia Mischung, Koichi Kusuhara, Frank T Saulsbury, Helen J Lachmann, Alison Bybee, Elizabeth M McDermott, Micaela La Regina, Juan I Arostegui, Josep M Campistol, Sharron Worthington, Kevin P High, Michael G Molloy, Nicholas Baker, Jeff L Bidwell, José L Castañer, Margo L Whiteford, P L Janssens-Korpola, Raffaele Manna, Richard J Powell, Patricia Woo, Pilar Solis, Kirsten Minden, Joost Frenkel, Jordi Yagüe, Rita M Mirakian, Graham A Hitman, Michael F McDermott.   

Abstract

OBJECTIVE: To investigate the prevalence of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among outpatients presenting with recurrent fevers and clinical features consistent with TRAPS.
METHODS: Mutational screening was performed in affected members of 18 families in which multiple members had symptoms compatible with TRAPS and in 176 consecutive subjects with sporadic (nonfamilial) "TRAPS-like" symptoms. Plasma concentrations of soluble tumor necrosis factor receptor superfamily 1A (sTNFRSF1A) were measured, and fluorescence-activated cell sorter analysis was used to measure TNFRSF1A shedding from monocytes.
RESULTS: Eight novel and 3 previously reported TNFRSF1A missense mutations were identified, including an amino acid deletion (Delta D42) in a Northern Irish family and a C70S mutation in a Japanese family, both reported for the first time. Only 3 TNFRSF1A variants were found in patients with sporadic TRAPS (4 of 176 patients). Evidence for nonallelic heterogeneity in TRAPS-like conditions was found: 3 members of the "prototype familial Hibernian fever" family did not possess C33Y, present in 9 other affected members. Plasma sTNFRSF1A levels were low in TRAPS patients in whom renal amyloidosis had not developed, but also in mutation-negative symptomatic subjects in 4 families, and in 14 patients (8%) with sporadic TRAPS. Reduced shedding of TNFRSF1A from monocytes was demonstrated in vitro in patients with the T50M and T50K variants, but not in those with other variants.
CONCLUSION: The presence of TNFRSF1A shedding defects and low sTNFRSF1A levels in 3 families without a TNFRSF1A mutation indicates that the genetic basis among patients with "TRAPS-like" features is heterogeneous. TNFRSF1A mutations are not commonly associated with nonfamilial recurrent fevers of unknown etiology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13130484     DOI: 10.1002/art.11215

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  42 in total

1.  Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever.

Authors:  H M Hoffman; A A Wanderer; D H Broide
Journal:  J Allergy Clin Immunol       Date:  2001-10       Impact factor: 10.793

2.  [Tumour necrosis factor receptor-associated periodic syndrome. A rare differential diagnosis of multiple sclerosis].

Authors:  P Günther; K Minden; W Hermann; J-P Schneider; A Wagner
Journal:  Nervenarzt       Date:  2005-10       Impact factor: 1.214

3.  Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series.

Authors:  Luca Cantarini; Orso Maria Lucherini; Rolando Cimaz; Donato Rigante; Cosima Tatiana Baldari; Franco Laghi Pasini; Mauro Galeazzi
Journal:  Rheumatol Int       Date:  2010-05-15       Impact factor: 2.631

Review 4.  The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.

Authors:  Luca Cantarini; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Luisa Costa; Giacomo Emmi; Elena Silvestri; Flora Magnotti; Maria Cristina Maggio; Eugenia Prinzi; Giuseppe Lopalco; Bruno Frediani; Rolando Cimaz; Mauro Galeazzi; Donato Rigante
Journal:  Clin Rheumatol       Date:  2014-06-24       Impact factor: 2.980

5.  The association of TNFRSF1A gene and MEFV gene mutations with adult onset Still's disease.

Authors:  Fulya Cosan; Zeliha Emrence; Gokhan Erbag; Hulya Azakli; Baris Yilmazer; Ayten Yazici; Sema Sirma Ekmekci; Neslihan Abaci; Duran Ustek; Ayse Cefle
Journal:  Rheumatol Int       Date:  2012-12-27       Impact factor: 2.631

6.  Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS).

Authors:  Adrian A Lobito; Fiona C Kimberley; Jagan R Muppidi; Hirsh Komarow; Adrianna J Jackson; Keith M Hull; Daniel L Kastner; Gavin R Screaton; Richard M Siegel
Journal:  Blood       Date:  2006-05-09       Impact factor: 22.113

7.  Role of tumour necrosis factor (TNF)-α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis.

Authors:  A Caminero; M Comabella; X Montalban
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

Review 8.  Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Donato Rigante; Giuseppe Lopalco; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Giacomo Emmi; Luisa Costa; Elena Silvestri; Laura Andreozzi; Florenzo Iannone; Mauro Galeazzi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2014-06-17       Impact factor: 2.980

9.  [Molecular diagnostics of hereditary fever syndromes. Familial Mediterranean fever (FMF), hyperimmunoglobulin D syndrome (HIDS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), cryopyrin-associated periodic syndrome (CAPS: FCAS, MWS, NOMID/CINCA)].

Authors:  C Timmann; R Horstmann
Journal:  Z Rheumatol       Date:  2009-11       Impact factor: 1.372

10.  Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour.

Authors:  Ian Todd; Paul M Radford; Kelly-Ann Draper-Morgan; Richard McIntosh; Susan Bainbridge; Peter Dickinson; Lama Jamhawi; Marios Sansaridis; Mary L Huggins; Patrick J Tighe; Richard J Powell
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.